Johnson & Johnson is preparing in the coming week – two to present the results of the final trials of its COVID-19 vaccine, according to a statement by the chief infectious disease specialist in the United States, Anthony Fauci. J&J reportedly plans to produce 100 million doses by April.
Johnson & Johnson (JNJ) rallied in early trading on Friday, after Anthony Fauci, the chief infectious disease physician in the United States, said Thursday that the company will provide data on the latest round of testing for its COVID-19 vaccine in the coming week.
Investors are waiting for the pharmaceutical giant to apply for permission from the FDA to use its vaccine in emergency situations, after which the stock could rise.
J&J shares have already surged after the company said last week that its vaccine was safe and elicited a significant immune response in 90% of early-stage volunteers. Final testing of the J&J vaccine was planned with 45,000 volunteers.
J&J vaccine approval in March and production of 100 million by April
On January 12, J&J Chief Scientist Paul Stoffels told Bloomberg that he is awaiting a US regulatory decision in March.
“We are continuing active negotiations with regulators, including the approval and verification of our production processes,” the company said. “We have begun production of our candidate vaccine and are confident in our ability to meet our 2021 supply commitments with governments, and we hope to share more details after some of these steps are completed.”
J&J board member Dr. Mark McClellan said Thursday in an interview with CNBC: “J&J is making a very large supply, struggling to produce both here in the US and around the world to get enough vaccines for 100 million Americans by spring. , by about April “.
If Johnson & Johnson’s vaccine is approved by the FDA for use, it will have great advantages over Pfizer (PFE) vaccines – BioNTech (BNTX) and Moderna (MRNA), which are currently licensed in the United States. J&J vaccine requires only one dose and does not require storage in cold temperatures.
Problems of vaccination against COVID-19 in the USA
Although the United States has signed major contracts to supply vaccines from manufacturers, the country is still behind its original vaccination schedule.
According to the Centers for Disease Control and Prevention, the US has averaged about 883,000 shots of vaccine per day over the past six days. Despite this, less than 50% of the 37,960,000 doses distributed ended up in human hands.
US President Joe Biden pointed to the problem of lack of state funding, insufficient number of vaccinated places and medical personnel.
The $ 1.9 trillion bill, developed by the president’s team, includes $ 20 billion in a national vaccination program in partnership with states and regions.
Biden signed 10 decrees on Thursday to tackle the COVID-19 pandemic, leveraging the wartime powers of the Defense Manufacturing Act, and plans to hit the target of 100 million vaccines within the first 100 days of his presidency.